Orchestra BioMed Holdings Inc. (OBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $560.38M
Last updated: Nov 17, 2026 at 4:15 PM ET
Orchestra BioMed Holdings Inc. (OBIO) Statistics
Orchestra BioMed Holdings (OBIO) has a market cap of $560.38M and an enterprise value of $568.54M. Revenue grew 1007.38% over the last 12 months from the 12 months before. It kept -182.50% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 1.46% above the market cap, as debt exceeds cash.
| Market Cap | $560.38M |
|---|---|
| Enterprise Value | $568.54M |
| Latest price (Nov 17, 2026) | $6.97 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 14.4x and 57.9x. Its year-end P/S ranged from 4.8x to 104.0x from 2022 to 2025.
| P/S Ratio | 14.4x |
|---|---|
| P/B Ratio | 57.9x |
Price Statistics
The stock is up 76.90% over 52 weeks and trades 17.34% above its 50-day average.
| Beta (1Y) | 1.53 |
|---|---|
| 52-Week Change | +76.90% |
| 1-Month Change | +23.36% |
| 3-Month Change | +25.59% |
| 6-Month Change | +74.25% |
| 5-Year Change | -40.06% |
| Total Return (1Y) | +76.90% |
| Total Return (3Y CAGR) | +0.88% |
| Total Return (5Y CAGR) | -6.73% |
| Return vs SPY (1Y) | +53.22% |
| Max Drawdown (1Y) | -34.77% |
| Max Drawdown (3Y) | -78.00% |
| Sharpe Ratio (1Y) | 0.79 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $5.94 |
| 200-Day Average | $4.66 |
| 52-Week Range | $3.46 to $7.45 |
| RSI (14 Days) | 65.9 |
| Average Volume (20 Days) | 542.48K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.25x current liabilities, and total debt is 4.62x shareholder equity.
| Current Ratio | 7.25x |
|---|---|
| Quick Ratio | 7.24x |
| Debt / Equity | 4.62x |
Returns and Efficiency
Return on invested capital is -96.95% over the last 12 months, against a 5-year average of -59.51%.
| Return on Equity (ROE) | -731.83% |
|---|---|
| Return on Assets (ROA) | -52.86% |
| Return on Invested Capital (ROIC) | -96.95% |
| Return on Capital Employed (ROCE) | -57.35% |
| ROA (5Y Average) | -42.60% |
| ROIC (5Y Average) | -59.51% |
| Asset Turnover | 0.29x |
| Inventory Turnover | 0.58x |
| Receivables Turnover | 583.29x |
| Cash Conversion Cycle | -14346 days |
Scores
OBIO has an Altman Z-Score of -2.86, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.86 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $31.21M over the last 12 months.
| Revenue | $31.21M |
|---|---|
| Revenue Growth (YoY) | +1007.38% |
| Gross Profit | $31.07M |
| Operating Income | -$60.97M |
| Pretax Income | -$57.20M |
| Net Income | -$56.95M |
| EBITDA | -$53.75M |
| EBIT | -$53.63M |
| Reported EPS (TTM) | -$0.75 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 7.22% of the $107.74M in total assets.
| Cash and Equivalents | $27.76M |
|---|---|
| Total Debt | $35.92M |
| Net Debt | $8.16M |
| Net Debt Per Share | $0.13 |
| Working Capital | $88.94M |
| Shareholder Equity | $7.78M |
| Book Value Per Share | $0.12 |
| Total Assets | $107.74M |
| Total Liabilities | $88.99M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $869.00K of capital spending, operating cash flow left -$64.18M of free cash flow.
| Operating Cash Flow | -$63.31M |
|---|---|
| Capital Expenditures | $869.00K |
| Free Cash Flow | -$64.18M |
| FCF Per Share | -$1.04 |
| Depreciation and Amortization | $1.09M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -195.39%.
| Gross Margin | 99.56% |
|---|---|
| Operating Margin | -195.39% |
| Pretax Margin | -183.31% |
| Net Margin | -182.50% |
| EBITDA Margin | -172.24% |
| EBIT Margin | -171.86% |
| FCF Margin | -205.66% |
Growth
Revenue grew 111.62% a year over 3 years.
| Revenue Growth (3Y CAGR) | +111.62% |
|---|---|
| Revenue Growth (5Y CAGR) | +42.48% |
| Book Value Per Share Growth (2Y CAGR) | -14.35% |
| Tangible Book Per Share Growth (2Y CAGR) | -14.35% |
Dividends and Yields
OBIO does not pay a dividend. Its free cash flow yield is -14.25%.
| FCF Yield | -14.25% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 3 similar companies, OBIO has the 2nd highest P/S.
P/S RatioPeer median 1.7x
ROICPeer median -11.69%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 14.4x vs 1.7x median |
|---|---|
| ROIC | -96.95% vs -11.69% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +1007.38% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at -86.61% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -86.61% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About OBIO
What is OBIO's market cap?
Orchestra BioMed Holdings has a market cap of $560.38M. Its enterprise value, which adds debt and subtracts cash, is $568.54M.
How many shares of OBIO are outstanding?
Orchestra BioMed Holdings has 64.62M shares outstanding. The count is up 23.83% from a year earlier.
Does OBIO pay a dividend?
No. Orchestra BioMed Holdings does not pay a dividend.
How much debt does OBIO have?
Orchestra BioMed Holdings has $35.92M of total debt and $27.76M of cash and equivalents, a net debt position of $8.16M.
OBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors